Strain Report - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Strain: F344/NHsd

Symbol: F344/NHsd
Strain: F344
Substrain: NHsd
Full Name: F344/NHsd
RGD ID: 61109
RRID: RGD_61109
Ontology ID: RS:0000363
Also known as: Fischer 344
Type: inbred
Source: Envigo
Origin: Strain originated from Curtiss and Dunning 1920 at Columbia University Institute for Cancer Research, To Heston 1949 (Billingham and Silvers 1959). To National Institutes of Health in 1951 (Hansen et al 1982). Subsequent sublines from Dunning or NIH.
Coat Color: Albino
Last Known Status: Unknown





Disease Annotations     Click to see Annotation Detail View


Phenotype Values via PhenoMiner     Click to see Annotation Detail View
Options:  View chart  |  Download data table  |  View expanded data table

Clinical Measurement
mean arterial blood pressure
body weight
red blood cell count
blood hemoglobin level
blood neutrophil count
blood lymphocyte count
blood monocyte count
blood eosinophil count
blood basophil count
hematocrit
mean corpuscular volume
plasma glucose level
serum creatinine level
plasma anion gap
heart wet weight
heart left ventricle wet weight
heart right ventricle wet weight
body length, nose to tail
body length, nose to rump
left kidney wet weight
liver wet weight
both adrenal glands wet weight
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
plasma insulin level
serum total cholesterol level
total white blood cell count
total serum bilirubin level
serum bicarbonate level
serum chloride level
serum potassium level
serum sodium level
serum calcium level
heart left ventricle weight to body weight ratio
plasma creatinine level
serum phosphate level
serum glucose level
serum albumin level
serum alanine aminotransferase activity level
serum alkaline phosphatase activity level
serum aspartate aminotransferase activity level
serum urea nitrogen level
serum total protein level
concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50)
logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50)
concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50)
logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50)
maximum contractile force per wet weight of aorta
acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel
urine calcium excretion rate
mean pulmonary arterial blood pressure
number of entries into a discrete space in an experimental apparatus
liver tumorous lesion number
volume of individual liver tumorous lesion
volume of liver occupied by tumorous lesions as percentage of total liver volume
plasma corticosterone level
bone mineral density
serum thyroid stimulating hormone level
maximum body weight loss to initial body weight ratio
artery neointimal hyperplastic lesion area
artery neointimal hyperplastic lesion area to total wall area ratio
inflammatory exudate neutrophil count
inflammatory exudate mononuclear leukocyte count
inflammatory exudate tumor necrosis factor level
inflammatory exudate nitric oxide level
inflammatory exudate leukotriene B4 level
inflammatory exudate lipoxin A4 level
inflammatory exudate leukotriene B4 level to lipoxin A4 level ratio
percentage of study population developing experimental arthritis during a period of time
percentage of study population developing experimental autoimmune neuritis during a period of time
volumetric bone mineral density
percentage of study population developing pituitary tumors that replace the entire gland during a period of time
percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time
percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time
percentage of study population developing pituitary gland hyperplastic lesions during a period of time
duration of grooming in an experimental apparatus
number of rearing movements in an experimental apparatus
lactotroph count to total pituicyte count ratio in prolactinoma
percentage of study population developing colorectal tumors during a period of time
food intake weight to body weight ratio
serum gamma-glutamyltransferase activity level
serum globulin level
absolute change in hematocrit
hepatocellular carcinoma tumor number
percentage of study population developing hepatocellular carcinoma during a period of time
water intake drink rate to body weight ratio
heart right ventricle weight to left ventricle plus septum weight ratio
artery neointimal hyperplastic lesion area including tunica media
volume of blood removed to total prehemorrhagic blood volume ratio

References

References - curated
1. Ahmadiyeh N, etal., Behav Genet 2005 Mar;35(2):189-98.
2. Alam I, etal., Bone. 2011 May 1;48(5):1169-77. Epub 2011 Feb 18.
3. Barbato JC, etal., J Appl Physiol 1998 Aug;85(2):530-6.
4. Baum AE, etal., Behav Brain Res. 2006 Feb 17;.
5. Baum AE, etal., Endocrinology 2004 Oct 28;.
6. Baum AE, etal., Endocrinology 2005 Feb;146(2):870-8. Epub 2004 Oct 28.
7. Bielefeld EC, etal., Hear Res. 2008 Apr 22;.
8. Dahlman I, etal., Eur J Immunol 1998 Jul;28(7):2188-96
9. De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.
10. Dracheva SV, etal., Immunogenetics 1999 Aug;49(9):787-91
11. Garrett MR, etal., J Am Soc Nephrol 2003 May;14(5):1175-87.
12. Joe B, etal., Arthritis Rheum 2002 Apr;46(4):1075-85.
13. Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.
14. Mattapallil MJ, et al., Invest Ophthalmol Vis Sci. 2008 May;49(5):1957-70. Epub 2008 Feb 15.
15. Mattapallil MJ, etal., J Immunol. 2008 May 15;180(10):6751-9.
16. Nosek K, etal., Behav Brain Funct. 2008 Jun 2;4(1):23.
17. Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13.
18. Pandey J, etal., Carcinogenesis 2004 May 27;.
19. Pandey J, etal., Mamm Genome. 2005 Nov;16(11):865-72. Epub 2005 Nov 11.
20. Personal communication with Harlan Laboratories
21. Remmers EF, etal., Arthritis Rheum 2002 Aug;46(8):2225-34.
22. Remmers EF, etal., Nat Genet 1996 Sep;14(1):82-5
23. RGD Automated Pipelines
24. Schlick NE, etal., Am J Physiol Cell Physiol. 2006 Dec;291(6):C1183-92. Epub 2006 Jul 19.
25. Sebkhi A, etal., Hypertension 1999 Apr;33(4):949-53.
26. Solberg LC, etal., Mamm Genome 2004 Aug;15(8):648-62.
27. Solberg LC, etal., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8.
28. Solberg Woods LC, etal., Mamm Genome. 2009 Aug 22.
29. Wendell DL and Gorski J, Mamm Genome 1997;8(11):823-9
30. Wendell DL, etal., Mamm Genome 2002 Nov;13(11):664-6.
31. Zhao L, etal., Circulation 2001 Jan 23;103(3):442-7.
32. Zhao L, etal., Nature. 2015 Aug 20;524(7565):356-60. doi: 10.1038/nature14620. Epub 2015 Aug 10.

Region

Cell Lines
Symbol
F344/NHsd-ES6/Qly

Strain QTL Data
Symbol Name Trait
Anxrr18 Anxiety related response QTL 18 body movement coordination trait   (VT:0005424)    
Anxrr19 Anxiety related response QTL 19 body movement coordination trait   (VT:0005424)    
Anxrr20 Anxiety related response QTL 20 body movement coordination trait   (VT:0005424)    
Bmd10 Bone mineral density QTL 10 femur mineral mass   (VT:0010011)    
Bmd11 Bone mineral density QTL 11 femur mineral mass   (VT:0010011)    
Bmd12 Bone mineral density QTL 12 femur mineral mass   (VT:0010011)    
Bmd13 Bone mineral density QTL 13 femur mineral mass   (VT:0010011)    
Bmd14 Bone mineral density QTL 14 femur mineral mass   (VT:0010011)    
Bmd15 Bone mineral density QTL 15 femur mineral mass   (VT:0010011)    
Bmd16 Bone mineral density QTL 16 femur mineral mass   (VT:0010011)    
Bmd17 Bone mineral density QTL 17 femur mineral mass   (VT:0010011)    
Bmd18 Bone mineral density QTL 18 femur mineral mass   (VT:0010011)    
Bmd6 Bone mineral density QTL 6 femur mineral mass   (VT:0010011)    
Bmd7 Bone mineral density QTL 7 femur mineral mass   (VT:0010011)    
Bmd8 Bone mineral density QTL 8 femur mineral mass   (VT:0010011)    
Bmd9 Bone mineral QTL density 9 femur mineral mass   (VT:0010011)    
Bss1 Bone structure and strength QTL 1 femur strength trait   (VT:0010010)    
Bss10 Bone structure and strength QTL 10 femur morphology trait   (VT:0000559)    
Bss105 Bone structure and strength QTL 105 femur strength trait   (VT:0010010)    
Bss106 Bone structure and strength QTL 106 femur strength trait   (VT:0010010)    
Bss107 Bone structure and strength QTL 107 femur strength trait   (VT:0010010)    
Bss108 Bone structure and strength QTL 108 femur strength trait   (VT:0010010)    
Bss109 Bone structure and strength QTL 109 femur strength trait   (VT:0010010)    
Bss11 Bone structure and strength QTL 11 femur morphology trait   (VT:0000559)    
Bss110 Bone structure and strength QTL 1 femur strength trait   (VT:0010010)    
Bss111 Bone structure and strength QTL 111 femur morphology trait   (VT:0000559)    
Bss112 Bone structure and strength QTL 112 femur morphology trait   (VT:0000559)    
Bss12 Bone structure and strength QTL 12 femur morphology trait   (VT:0000559)    
Bss13 Bone structure and strength QTL 13 femur strength trait   (VT:0010010)    
Bss14 Bone structure and strength QTL 14 femur morphology trait   (VT:0000559)    
Bss15 Bone structure and strength QTL 15 femur width   (VT:1000666)    
Bss16 Bone structure and strength QTL 16 femur morphology trait   (VT:0000559)    
Bss17 Bone structure and strength QTL 17 femur morphology trait   (VT:0000559)    
Bss18 Bone structure and strength QTL 18 femur width   (VT:1000666)    
Bss19 Bone structure and strength QTL 19 femur morphology trait   (VT:0000559)    
Bss2 Bone structure and strength QTL 2 femur strength trait   (VT:0010010)    
Bss20 Bone structure and strength QTL 20 femur morphology trait   (VT:0000559)    
Bss21 Bone structure and strength QTL 21 femur morphology trait   (VT:0000559)    
Bss3 Bone structure and strength QTL 3 femur morphology trait   (VT:0000559)    
Bss4 Bone structure and strength QTL 4 femur strength trait   (VT:0010010)    
Bss5 Bone structure and strength QTL 5 femur strength trait   (VT:0010010)    
Bss6 Bone structure and strength QTL 6 lumbar vertebra strength trait   (VT:0010574)    
Bss7 Bone structure and strength QTL 7 femur strength trait   (VT:0010010)    
Bss8 Bone structure and strength QTL 8 lumbar vertebra strength trait   (VT:0010574)    
Bss9 Bone structure and strength QTL 9 femur morphology trait   (VT:0000559)    
Bvd1 Brain ventricular dilatation QTL 1 brain ventricle morphology trait   (VT:0000822)    
Bvd2 Brain ventricular dilatation QTL 2 brain ventricle morphology trait   (VT:0000822)    
Bvd3 Brain ventricular dilatation QTL 3 brain ventricle morphology trait   (VT:0000822)    
Bvd4 Brain ventricular dilatation QTL 4 brain ventricle morphology trait   (VT:0000822)    
Bvd5 Brain ventricular dilatation QTL 5 brain ventricle morphology trait   (VT:0000822)    
Bw85 Body weight QTL 85 body mass   (VT:0001259)    
Bw86 Body weight QTL 86 body mass   (VT:0001259)    
Bw87 Body weight QTL 87 body mass   (VT:0001259)    
Bw88 Body weight QTL 88 body mass   (VT:0001259)    
Bw89 Body weight QTL 89 body mass   (VT:0001259)    
Bw90 Body weight QTL 90 body mass   (VT:0001259)    
Bw91 Body weight QTL 91 body mass   (VT:0001259)    
Bw92 Body weight QTL 92 body mass   (VT:0001259)    
Bw93 Body weight QTL 93 body mass   (VT:0001259)    
Cia1 Collagen induced arthritis QTL 1 joint integrity trait   (VT:0010548)    
Cia2 Collagen induced arthritis QTL 2 joint integrity trait   (VT:0010548)    
Cia20 Collagen induced arthritis QTL 20 joint integrity trait   (VT:0010548)    
Cia21 Collagen induced arthritis QTL 21 joint integrity trait   (VT:0010548)    
Cia3 Collagen induced arthritis QTL 3 joint integrity trait   (VT:0010548)    
Cia4 Collagen induced arthritis QTL 4 joint integrity trait   (VT:0010548)    
Cia5 Collagen induced arthritis QTL 5 joint integrity trait   (VT:0010548)    
Cia8 Collagen induced arthritis QTL 8 joint integrity trait   (VT:0010548)    
Cm15 Cardiac mass QTL 15 heart right ventricle mass   (VT:0007033)    
Cm25 Cardiac mass QTL 25 heart left ventricle mass   (VT:0007031)    
Despr1 Despair related QTL 1 locomotor behavior trait   (VT:0001392)    
Despr10 Despair related QTL 10 locomotor behavior trait   (VT:0001392)    
Despr11 Despair related QTL 11 locomotor behavior trait   (VT:0001392)    
Despr12 Despair related QTL 12 locomotor behavior trait   (VT:0001392)    
Despr13 Despair related QTL 13 locomotor behavior trait   (VT:0001392)    
Despr14 Despair related QTL 14 locomotor behavior trait   (VT:0001392)    
Despr15 Despair related QTL 15 locomotor behavior trait   (VT:0001392)    
Despr2 Despair related QTL 2 locomotor behavior trait   (VT:0001392)    
Despr3 Despair related QTL3 locomotor behavior trait   (VT:0001392)    
Despr4 Despair related QTL 4 locomotor behavior trait   (VT:0001392)    
Despr5 Despair related QTL 5 locomotor behavior trait   (VT:0001392)    
Despr6 Despair related QTL 6 locomotor behavior trait   (VT:0001392)    
Despr7 Despair related QTL 7 locomotor behavior trait   (VT:0001392)    
Despr8 Despair related QTL 8 locomotor behavior trait   (VT:0001392)    
Despr9 Despair related QTL 9 locomotor behavior trait   (VT:0001392)    
Eau4 Experimental allergic uveoretinitis QTL 4 uvea integrity trait   (VT:0010551)    
Eau5 Experimental allergic uveoretinitis QTL 5 uvea integrity trait   (VT:0010551)    
Eau6 Experimental allergic uveoretinitis QTL 6 uvea integrity trait   (VT:0010551)    
Eau7 Experimental allergic uveoretinitis QTL 7 uvea integrity trait   (VT:0010551)    
Eau8 Experimental allergic uveoretinitis QTL 8 uvea integrity trait   (VT:0010551)    
Eau9 Experimental allergic uveoretinitis QTL 9 uvea integrity trait   (VT:0010551)    
Edpm1 Estrogen-dependent pituitary mass QTL 1 pituitary gland mass   (VT:0010496)    
Edpm10 Estrogen-dependent pituitary mass QTL 10 pituitary gland mass   (VT:0010496)    
Edpm11 Estrogen-dependent pituitary mass QTL 11 pituitary gland mass   (VT:0010496)    
Edpm12 Estrogen-dependent pituitary mass QTL 12 pituitary gland mass   (VT:0010496)    
Edpm2 Estrogen-dependent pituitary mass QTL 2 pituitary gland mass   (VT:0010496)    
Edpm3 Estrogen-dependent pituitary mass QTL 3 pituitary gland mass   (VT:0010496)    
Edpm5 Estrogen-dependent pituitary mass QTL 5 pituitary gland mass   (VT:0010496)    
Edpm9 Estrogen-dependent pituitary mass QTL 9 pituitary gland mass   (VT:0010496)    
Gluco41 Glucose level QTL 41 blood glucose amount   (VT:0000188)    
Gluco42 Glucose level QTL 42 blood glucose amount   (VT:0000188)    
Gluco43 Glucose level QTL 43 blood glucose amount   (VT:0000188)    
Gluco44 Glucose level QTL 44 blood glucose amount   (VT:0000188)    
Gluco45 Glucose level QTL 45 blood glucose amount   (VT:0000188)    
Gluco46 Glucose level QTL 46 blood glucose amount   (VT:0000188)    
Gluco47 Glucose level QTL 47 blood glucose amount   (VT:0000188)    
Gluco48 Glucose level QTL 48 blood glucose amount   (VT:0000188)    
Gluco49 Glucose level QTL 49 blood glucose amount   (VT:0000188)    
Gluco50 Glucose level QTL 50 blood glucose amount   (VT:0000188)    
Gluco51 Glucose level QTL 51 blood glucose amount   (VT:0000188)    
Gluco52 Glucose level QTL 52 blood glucose amount   (VT:0000188)    
Gluco53 Glucose level QTL 53 blood glucose amount   (VT:0000188)    
Gluco54 Glucose level QTL 54 blood glucose amount   (VT:0000188)    
Gluco55 Glucose level QTL 55 blood glucose amount   (VT:0000188)    
Hcar1 Hepatocarcinoma resistance QTL 1 liver integrity trait   (VT:0010547)    
Hcar2 Hepatocarcinoma resistance QTL 2 liver integrity trait   (VT:0010547)    
Hcar3 Hepatocarcinoma resistance QTL 3 liver integrity trait   (VT:0010547)    
Hcas1 Hepatocarcinoma susceptibility QTL 1 liver integrity trait   (VT:0010547)    
Hcas2 Hepatocarcinoma susceptibility QTL 2 liver integrity trait   (VT:0010547)    
Insul12 Insulin level QTL 12 blood insulin amount   (VT:0001560)    
Insul13 Insulin level QTL 13 blood insulin amount   (VT:0001560)    
Insul14 Insulin level QTL 14 blood insulin amount   (VT:0001560)    
Mcs30 Mammary carcinoma susceptibility QTL 30 mammary gland integrity trait   (VT:0010552)    
Sradr1 Stress Responsive Adrenal Weight QTL 1 adrenal gland mass   (VT:0010420)    
Sradr2 Stress Responsive Adrenal Weight QTL 2 adrenal gland mass   (VT:0010420)    
Sradr3 Stress Responsive Adrenal Weight QTL 3 adrenal gland mass   (VT:0010420)    
Sradr4 Stress Responsive Adrenal Weight QTL 4 adrenal gland mass   (VT:0010420)    
Sradr5 Stress Responsive Adrenal Weight QTL 5 adrenal gland mass   (VT:0010420)    
Sradr6 Stress Responsive Adrenal Weight QTL 6 adrenal gland mass   (VT:0010420)    
Srcrt1 Stress Responsive Cort QTL1 blood corticosterone amount   (VT:0005345)    
Srcrt2 Stress Responsive Cort QTL 2 blood corticosterone amount   (VT:0005345)    
Srcrt3 Stress Responsive Cort QTL 3 blood corticosterone amount   (VT:0005345)    
Srcrt4 Stress Responsive Cort QTL 4 blood corticosterone amount   (VT:0005345)    
Srcrt5 Stress Responsive Cort QTL 5 blood corticosterone amount   (VT:0005345)    
Srcrtb1 Stress Responsive Cort Basal QTL 1 blood corticosterone amount   (VT:0005345)    
Srcrtb2 Stress Responsive Cort Basal QTL 2 blood corticosterone amount   (VT:0005345)    
Stresp10 Stress response QTL 10 stress-related behavior trait   (VT:0010451)    
Stresp11 Stress response QTL 11 stress-related behavior trait   (VT:0010451)    
Stresp12 Stress response QTL 12 stress-related behavior trait   (VT:0010451)    
Stresp13 Stress response QTL 13 stress-related behavior trait   (VT:0010451)    
Stresp4 Stress response QTL 4 blood corticosterone amount   (VT:0005345)    
Stresp5 Stress response QTL 5 blood corticosterone amount   (VT:0005345)    
Stresp8 Stress response QTL 8 stress-related behavior trait   (VT:0010451)    
Stresp9 Stress response QTL 9 stress-related behavior trait   (VT:0010451)    
Thshl1 Thyroid stimulating hormone level QTL 1 blood thyroid-stimulating hormone amount   (VT:0005119)    
Thshl2 Thyroid stimulating hormone level QTL 2 blood thyroid-stimulating hormone amount   (VT:0005119)    
Damaging Variants
Number of Damaging Variants
SampleRnor_6.0Rnor_5.0RGSC_v3.4
F344/NHsd (KNAW) 782
F344/NHsd (ICAHN) 508


Additional Information

RGD Curation Notes
Note Type Note Reference
strain_drgs_chems Displays pituitary tumor growth in response to chronic estrogen stimulation 629581
strain_life_disease Resistant to estrogen-induced uterine inflammation and infection (pyometritis) 1559291
strain_life_disease These are resistant to IRBP induced uveitis 2293749
strain_other On the basis of work, these females performed significantly better than the COP females. 1358977
strain_other These are used for sleeping beauty mutants 2290040
strain_other These have shorter survival time after controlled hemorrhage than BN/HsdMcwiCrl but longer than DA/OlaHsd. 2302114